ESSA Pharma (EPIX) Competitors $1.75 0.00 (0.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends EPIX vs. TNGX, BTMD, SNDL, CMRX, TRVI, VYGR, LFVN, ITOS, YMAB, and AQSTShould you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Tango Therapeutics (TNGX), biote (BTMD), SNDL (SNDL), Chimerix (CMRX), Trevi Therapeutics (TRVI), Voyager Therapeutics (VYGR), LifeVantage (LFVN), iTeos Therapeutics (ITOS), Y-mAbs Therapeutics (YMAB), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. ESSA Pharma vs. Tango Therapeutics biote SNDL Chimerix Trevi Therapeutics Voyager Therapeutics LifeVantage iTeos Therapeutics Y-mAbs Therapeutics Aquestive Therapeutics ESSA Pharma (NASDAQ:EPIX) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, community ranking, profitability, institutional ownership, valuation and earnings. Does the MarketBeat Community believe in EPIX or TNGX? ESSA Pharma received 321 more outperform votes than Tango Therapeutics when rated by MarketBeat users. Likewise, 75.87% of users gave ESSA Pharma an outperform vote while only 73.68% of users gave Tango Therapeutics an outperform vote. CompanyUnderperformOutperformESSA PharmaOutperform Votes34975.87% Underperform Votes11124.13% Tango TherapeuticsOutperform Votes2873.68% Underperform Votes1026.32% Do insiders and institutionals hold more shares of EPIX or TNGX? 75.1% of ESSA Pharma shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 14.7% of ESSA Pharma shares are owned by insiders. Comparatively, 6.3% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer EPIX or TNGX? In the previous week, ESSA Pharma had 2 more articles in the media than Tango Therapeutics. MarketBeat recorded 2 mentions for ESSA Pharma and 0 mentions for Tango Therapeutics. ESSA Pharma's average media sentiment score of 1.22 beat Tango Therapeutics' score of 0.00 indicating that ESSA Pharma is being referred to more favorably in the media. Company Overall Sentiment ESSA Pharma Positive Tango Therapeutics Neutral Do analysts recommend EPIX or TNGX? ESSA Pharma currently has a consensus price target of $9.50, indicating a potential upside of 442.86%. Tango Therapeutics has a consensus price target of $13.14, indicating a potential upside of 361.15%. Given ESSA Pharma's higher probable upside, analysts clearly believe ESSA Pharma is more favorable than Tango Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ESSA Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, EPIX or TNGX? ESSA Pharma has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Which has preferable valuation and earnings, EPIX or TNGX? ESSA Pharma has higher earnings, but lower revenue than Tango Therapeutics. ESSA Pharma is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioESSA PharmaN/AN/A-$28.54M-$0.64-2.73Tango Therapeutics$36.53M8.38-$101.74M-$1.18-2.42 Is EPIX or TNGX more profitable? ESSA Pharma has a net margin of 0.00% compared to Tango Therapeutics' net margin of -284.42%. ESSA Pharma's return on equity of -21.64% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ESSA PharmaN/A -21.64% -21.02% Tango Therapeutics -284.42%-49.64%-32.00% SummaryESSA Pharma beats Tango Therapeutics on 12 of the 17 factors compared between the two stocks. Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPIX vs. The Competition Export to ExcelMetricESSA PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.68M$6.23B$5.21B$9.15BDividend YieldN/A2.94%5.13%4.03%P/E Ratio-2.739.5488.0817.36Price / SalesN/A309.511,243.2778.03Price / CashN/A61.4443.7535.97Price / Book0.626.055.314.79Net Income-$28.54M$154.90M$122.62M$225.00M7 Day Performance1.16%-0.32%0.61%2.62%1 Month Performance9.37%0.43%2.56%3.81%1 Year Performance-80.07%3.08%25.79%20.10% ESSA Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPIXESSA Pharma3.9145 of 5 stars$1.75flat$9.50+442.9%-80.1%$77.68MN/A-2.7350Short Interest ↓News CoveragePositive NewsTNGXTango Therapeutics2.54 of 5 stars$2.84-3.1%$13.14+362.8%-73.9%$305.07M$43.38M-2.4190BTMDbiote2.8232 of 5 stars$5.55-1.8%$9.11+64.1%+43.5%$301.57M$193.06M21.35194News CoveragePositive NewsGap DownSNDLSNDL3.5169 of 5 stars$1.82-1.4%$3.25+79.1%+23.6%$301.33M$911.22M-5.852,516Positive NewsCMRXChimerix4.3861 of 5 stars$3.35+3.1%$8.50+153.7%+284.0%$301.29M$159,000.00-3.5690Gap DownTRVITrevi Therapeutics3.56 of 5 stars$3.89+1.8%$9.31+139.4%+178.5%$299.01MN/A-8.8420Positive NewsVYGRVoyager Therapeutics4.8895 of 5 stars$5.25-3.7%$15.97+204.1%-32.9%$286.79M$163.78M7.39100LFVNLifeVantage4.3944 of 5 stars$22.88+1.6%$26.00+13.6%+329.0%$286.57M$196.01M71.50260Short Interest ↓ITOSiTeos Therapeutics4.0348 of 5 stars$7.78+0.3%$22.25+186.0%-24.2%$284.24M$35M-2.4790YMABY-mAbs Therapeutics2.5421 of 5 stars$6.32-8.3%$20.89+230.5%-34.3%$283.07M$84.55M-11.70150AQSTAquestive Therapeutics1.8966 of 5 stars$3.09+0.3%$11.00+256.0%+27.0%$281.74M$58.90M-6.87160Short Interest ↑ Related Companies and Tools Related Companies Tango Therapeutics Alternatives biote Alternatives SNDL Alternatives Chimerix Alternatives Trevi Therapeutics Alternatives Voyager Therapeutics Alternatives LifeVantage Alternatives iTeos Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Aquestive Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EPIX) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump secret stock already up 339% In this video, you’ll also get nine other Trump-connected investments… All of which we believe could have a...Porter & Company | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
